A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib

Condition:   Gastrointestinal Stromal Tumor(GIST) Interventions:   Drug: Ripretinib;   Drug: Sunitinib Sponsor:   Zai Lab (Shanghai) Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials